CSIMarket Company Name, Ticker, Customers, else..
 
Inventiva S a   (NASDAQ: IVA)
Other Ticker:  
 
 
Price: $2.3300 $-0.19 -7.540%
Day's High: $2.465 Week Perf: 7.87 %
Day's Low: $ 2.30 30 Day Perf: -0.85 %
Volume (M): 13 52 Wk High: $ 4.50
Volume (M$): $ 29 52 Wk Avg: $2.87
Open: $2.45 52 Wk Low: $1.53



 Market Capitalization (Millions $) 106
 Shares Outstanding (Millions) 45
 Employees 90
 Revenues (TTM) (Millions $) 46
 Net Income (TTM) (Millions $) -124
 Cash Flow (TTM) (Millions $) 97
 Capital Exp. (TTM) (Millions $) 0

Inventiva S A
Inventiva S.a is a biopharmaceutical company based in France. It specializes in the development of small molecule drugs for the treatment of various diseases, particularly in the areas of fibrosis, oncology, and rare diseases. The company's main focus is on the discovery and development of therapeutic candidates that target nuclear receptors, which are key regulators of gene expression. Inventiva's innovative approach and expertise in drug discovery have led to the advancement of several promising drug candidates in its pipeline. The company's goal is to deliver effective and safe therapies to patients in need, addressing unmet medical needs and improving overall healthcare outcomes.


   Company Address: 50 rue de Dijon Daix 21121
   Company Phone Number: 3 80 44 75 00   Stock Exchange / Ticker: NASDAQ IVA


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMRN      % 
GLPG      % 
LQDA      % 
MIRM      % 
SRPT      % 
XERS      % 
• View Complete Report
   



Cytodyn Inc

CYDY, decline in the operating conduct during the fiscal span ending second quarter of 2025

Following the large companies in the Major Pharmaceutical Preparations sector, a number of smaller businesses are impending with the respective numbers. CYDY said it has announced operating loss of $-3.707 million, for the second quarter of 2025.

Cnbx Pharmaceuticals Inc

Observing the first quarter of 2025 results, CNBKs' saw revenue were unaffected from the same period a year prior

For the first quarter of 2025 earnings season Cnbx Pharmaceuticals Inc reached 0 of $0.00 per share compare to $0.00 a year prior and from $0.00 per share from the previous financial reporting period. The revenue remained unaffected to $0.00 million from $0.09 million in the same financial reporting period a year prior and sequentially from $0.01 million.

Lexaria Bioscience Corp

Extraordinary earnings by Lexaria Bioscience Corp in the fiscal span ending November 30 2024

Lexaria Bioscience Corp announced in the fiscal span ending November 30 2024 surge in revenue by 21.579 % to $0.18 million from the comparable reporting season a year ago, but it has increased a deficit per share at $-0.16 per share. Major Pharmaceutical Preparations company's has clearly outperformed its sector peers on the business facet, as the rest of the Major Pharmaceutical Preparations sector express 7.10% in the same period revenue rise thus far.

Lifecore Biomedical Inc

Looking into second quarter of 2025 performance, the Major Pharmaceutical Preparations company's had sturdy revenue rise

For the September to November 24 2024 time-frame LFCR Diminishing Returns have expanded of $-0.25 per share compare to $0.39 a year ago and EPS improved from $-0.53 per share from the prior reporting period. The Revenue advanced by 7.1 % to $32.08 million from $29.96 million in the similar reporting period a year ago and sequentially revenue surged by 31.562 % from $24.39 million.

Essa Pharma Inc

Essa Pharma Inc. Reports Impressive Operating Income of $7.69 Million for Q3 2024!

The Major Pharmaceutical Preparations sector consultants start to analyze the fourth quarter of 2024 earnings. Today those consultants observe operating income of $7.694578 million, from the EPIX, as it hasn't stated any revenue thus far, for the respective July to September 30 2024 reporting period.










Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com